Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review

Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

Indirubin might help treat glioblastoma

Indirubin might help treat glioblastoma

Study: No evidence of increased risk of leukaemia near nuclear power plants

Study: No evidence of increased risk of leukaemia near nuclear power plants

Men more likely to succumb to cancer

Men more likely to succumb to cancer

Affymetrix commences shipment of gene profiling reagents

Affymetrix commences shipment of gene profiling reagents

Two studies on childhood leukemia

Two studies on childhood leukemia

Hutchinson Center receives $20M NIH grant to eradicate HIV infection

Hutchinson Center receives $20M NIH grant to eradicate HIV infection

Cancer Cell publishes Epizyme and collaborators' breakthrough research on MLL

Cancer Cell publishes Epizyme and collaborators' breakthrough research on MLL

Amgen, Micromet to expand development of BiTE antibodies against solid tumors

Amgen, Micromet to expand development of BiTE antibodies against solid tumors

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Common cell pathway could lead to new treatments for autoimmune diseases and cancer

Common cell pathway could lead to new treatments for autoimmune diseases and cancer

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

LFB receives U.S. patent titled 'Monoclonal Antibodies with Enhanced ADCC Function'

LFB receives U.S. patent titled 'Monoclonal Antibodies with Enhanced ADCC Function'

New NCCN Clinical Practice Guideline on Malignant Pleural Mesothelioma

New NCCN Clinical Practice Guideline on Malignant Pleural Mesothelioma

Half-matched transplants widen donor pool for leukemia and lymphoma

Half-matched transplants widen donor pool for leukemia and lymphoma

TGen presents two key studies at 14th World Conference on Lung Cancer

TGen presents two key studies at 14th World Conference on Lung Cancer

Eighteen scientists receive Damon Runyon Cancer Research Foundation awards

Eighteen scientists receive Damon Runyon Cancer Research Foundation awards

Induced pluripotent cells may make embryonic stem cells unnecessary

Induced pluripotent cells may make embryonic stem cells unnecessary

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.